GlycoMimetics Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GlycoMimetics stock.
View analyst ratings for GlycoMimetics or view top-rated stocks.

Wall Street analysts have given GlycoMimetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GlycoMimetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

GlycoMimetics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 1,100,000 shares, a drop of 28.6% from the August 15th total of 1,540,000 shares. Based on an average daily trading volume, of 460,600 shares, the short-interest ratio is currently 2.4 days. Approximately 2.7% of the company's stock are sold short.
View GlycoMimetics' Short Interest.

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for GlycoMimetics.

GlycoMimetics, Inc. (NASDAQ:GLYC) released its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.03.
View GlycoMimetics' earnings history.

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLYC shares have decreased by 26.9% and is now trading at $2.15.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 1 year price targets for GlycoMimetics' shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate GlycoMimetics' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 458.1% from the stock's current price.
View analysts' price targets for GlycoMimetics or view top-rated stocks among Wall Street analysts.

Some companies that are related to GlycoMimetics include KalVista Pharmaceuticals (KALV), Evolus (EOLS), BELLUS Health (BLU), Geron (GERN), Kezar Life Sciences (KZR), Akouos (AKUS), Eliem Therapeutics (ELYM), Arbutus Biopharma (ABUS), Kindred Biosciences (KIN), Magenta Therapeutics (MGTA), PDS Biotechnology (PDSB), Cue Biopharma (CUE), Provention Bio (PRVB), Atossa Therapeutics (ATOS) and Nanobiotix (NBTX).
View all of GLYC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

GlycoMimetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.41%), Dimensional Fund Advisors LP (2.29%), BlackRock Inc. (1.72%), Renaissance Technologies LLC (1.47%), Millennium Management LLC (1.33%) and Geode Capital Management LLC (0.68%). Company insiders that own GlycoMimetics stock include Bvf Partners L P/Il and Daniel M Junius.
View institutional ownership trends for GlycoMimetics.

GLYC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Geode Capital Management LLC, Northern Trust Corp, Morgan Stanley, Morgan Stanley, and AQR Capital Management LLC.
View insider buying and selling activity for GlycoMimetics or view top insider-selling stocks.

GLYC stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Tibra Equities Europe Ltd, Renaissance Technologies LLC, Susquehanna Fundamental Investments LLC, Goldman Sachs Group Inc., QS Investors LLC, and XTX Topco Ltd. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il, and Daniel M Junius.
View insider buying and selling activity for GlycoMimetics or or view top insider-buying stocks.

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLYC stock can currently be purchased for approximately $2.15.

GlycoMimetics has a market capitalization of $110.81 million and generates $10.16 million in revenue each year. The biotechnology company earns $-51,030,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

GlycoMimetics employs 54 workers across the globe.

The official website for GlycoMimetics is www.glycomimetics.com.

GlycoMimetics is headquartered at 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850.

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 243-1201 or via email at [email protected].